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A B S T R A C T
Introduction: Methohexital has replaced amobarbital duringWada testing atmany centers. The objective
of our study was to compare the use of methohexital and amobarbital during Wada testing regarding
language and memory lateralization quotients as well as speech arrest times.
Methods: A chart review of 582 consecutive patients undergoing 1041Wada-procedures was performed
(left = 60, right = 63, bilateral = 459). Language lateralization was calculated based on duration of speech
arrest using a laterality index, deﬁned as (L  R)/(L + R). Memory lateralization was expressed as
percentage of retained objects and laterality quotient.
Results: Language and memory lateralization revealed a similar distribution with amobarbital and
methohexital. Speech arrest after left and right-sided injection was signiﬁcantly longer in the
amobarbital group as compared to the methohexital group. Language lateralization did not differ in the
two groups. Percentage of retainedmemory items was higher in the methohexital group and there were
fewer presented test items in the methohexital group.
Discussion: Language and memory testing during the Wada test can successfully be performed with
methohexital instead of amobarbital. The shorter half-life of methohexital allows repeated injections
and shorter interhemispheric testing intervals, but also shortens the testing window.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Since the 1940s, intracarotid amobarbital injection has been
used in the presurgical language assessment of epilepsy patients.1
Memory testing during theWada test was added byMilner et al. in
1962.2 During a recent shortage amobarbital was replaced by
methohexital. Only limited information is available on methohex-
ital as an anesthetic in theWada test.3–7 The objective of our study
was to test methohexital as an anesthetic agent in the Wada test
and to compare methohexital and amobarbital regarding language
andmemory lateralization quotients as well as speech arrest times
during the Wada test.* Corresponding author at: Division of Epilepsy and Clinical Neurophysiology,
Children’s Hospital Boston, 300 Longwood Ave, Boston, MA 02445, United States.
Tel.: +1 617 355 2443.
E-mail address: tobias.loddenkemper@childrens.harvard.edu
(T. Loddenkemper).
1 We commemorate Dr. Dudley S. Dinner who passed away during the
completion of the manuscript.
1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.08.0022. Methods
A retrospective chart review of 582 consecutive Wada tests
carried out at the Cleveland Clinic between 1997 and 2003 was
performed. All patients (294 males) were included. A total of 1041
injections (left = 60; right = 63, bilateral = 459) were analyzed.
Mean age was 32 years ranging from 5 to 84 years. Patients
underwent left (n = 60), right (n = 63), or bilateral (n = 459) internal
carotid artery catheterization and injection.
Amobarbital was used from 1997 until March 2001. After that
date amobarbital was difﬁcult to obtain and it was replaced by
methohexital. Angiography was performed and all patients were
monitored with simultaneous EEG recording according to the 10–
20 system. An epileptologist was present during the procedure.
Methohexital (133 patients; 3–10 mg) or amobarbital (449
patients; 75–250 mg) was injected (Table 1). Amobarbital
(usually 100 mg) was given as a single injection over 3–5 s
(handpush). Methohexital (usually 3 mg) was given over 3–5 s
intravenously (handpush). In case of incomplete hemiparesis
after initial injection an additional dose of Methohexital (2 mg) or
Amobarbital (25 mg) was given. Rarely an additional dose was
given 30 s later. Effective injection was demonstrated byvier Ltd. All rights reserved.
Table 1
Patient descriptives and demographics.
Amobarbital Methohexital All
Demographics
Patients 449 133 582
Mean age in years (range) 31.96 (6–75) 32.7 (5–84) 32.1 (5–84)
Males 230 64 294
Procedures 804 237 1041
Bilateral procedures 355 104 459
Left-sided procedures only 44 16 60
Right-sided procedures only 50 13 63
Barbiturate dose
Average dose in all right-sided procedures in mg (range) 108 (75–175) 5 (3–7) –
Average dose in all left-sided procedures in mg (range) 115 (75–325) 5 (3–10) –
Type of MRI lesion
MCD 43 (10%) 14 (10%) 57 (10%)
Hippocampal atrophy/MTS 137 (30%) 33 (25%) 170 (29%)
Tumor 103 (23%) 36 (27%) 139 (23%)
AVM/cavernous angioma 20 (4%) 4 (3%) 24 (5%)
Encephalomalcia/trauma 37 (8%) 12 (9%) 49 (9%)
Other MRI lesions 26 (6%) 8 (6%) 33 (6%)
No lesion/normal 83 (19%) 27 (20%) 110 (18%)
Sum 449 (77%) 133 (23%) 582
Lateralization of MRI lesions (n=472)
Lesion left 174 (48%) 65 (61%) 239 (50%)
Lesion right 163 (44%) 29 (28%) 192 (41%)
Lesion bilateral 29 (8%) 12 (11%) 41 (9%)
Sum 366 (77%) 106 (23%) 472
MCD—malformation of cortical development; MTS—mesial temporal sclerosis; AVM—arteriovenous malformation; TS—tuberous sclerosis; SWS—Sturge–Weber syndrome.
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tions was 30–45 min between amobarbital doses and 15–30 min
between methohexital doses.
Language testing included counting, repetition, spontaneous
speech, object naming, and reading words. Absolute duration (in s)
of speech arrest (return to normal speech) after right and left
injection was documented. Language lateralization was calculated
in bilaterally injected patients based on the laterality index (LI)
deﬁned as (Left speech arrest time  Right speech arrest time)/
(Left speech arrest time + Right speech arrest time), cutoff >0.5
(left) or <0.5 (right).8 Patients with a laterality index of 0.5 to
0.5 were considered bilateral dependent. Patients with no speech
arrest after right and left injection were considered bilateral
independent.8,9
The memory test paradigm consisted of presentation of 9–20
words and objects. Number of items was determined by duration
of hemiparesis. Presented items included function words and
objectwords aswell as designs and pictures. Fifteen to 30 min after
resolution of the hemiparesis, memorywas tested using a selection
paradigm. The patient was presented with four different choices
and had to select the correct picture or word. The percentage of
retained objects was calculated as a separate ratio (number of
retained items/number of presented items) for each hemisphere.
Memory lateralization was determined by the larger percentage of
retained objects and words in patients with bilateral injections.
Additional details on Wada test methodology have been described
elsewhere.10
Statistical testing was performed with SPSS 10.0 (Chicago, IL,
USA). For all statistical comparisons, a signiﬁcance level of 0.05was
accepted.
3. Results
3.1. Demographics
Patient descriptives and intracranial lesions did not differ
between both compared patient populations (Table 1).3.2. Methohexital
Details on speech arrest times are listed in Table 1. Language
lateralization in patients with bilateral methohexital injections
was left in 76%, right in 5.9%, bilateral dependent in 16.3% and
bilateral independent in 1.9% (Table 2). Memory lateralization was
predominantly left in 60.6%, bilateral in 16.3%, and predominantly
right in 23.1% (Table 2).
3.3. Amobarbital
Language lateralization in patients with bilateral injections was
left in 79.7%, right in 5.9%, bilateral dependent in 13% and bilateral
independent in 1.4% (Table 2). Memory lateralization was
predominantly left 60.8%, predominantly right in 30.7% and
bilateral in 8.5% (Table 2).
3.4. Comparison between amobarbital and methohexital
Speech arrest after left and right-sided injection was signiﬁ-
cantly longer in the amobarbital group as compared to the
methohexital group (p < 0.05 left; p < 0.01 right). Language
lateralization did not differ in the two groups. Also, the two
groups did not differ in terms of memory lateralization quotients,
although an increased number of patients with bilateral memory
representation was seen in the methohexital group (Table 2). The
percentage of retained objects after methohexital was signiﬁcantly
higher than after amobarbital (p < 0.0001). During methohexital
testing fewer items (objects and words) for memory testing were
presented as compared to amobarbital (p < 0.0001).
3.5. Language lateralization in patients with bilateral injections
3.5.1. Left-sided language
In patients with left-sided language lateralization after
amobarbital injection median left-sided speech arrest time was
142 s and median right-sided speech arrest duration was 0 s. In
Table 2
Language and memory lateralization results.
Amobarbital Methohexital
Speech arrest times
Median speech arrest in all left-sided
injections in s (range)**
130 (0–723) 5 (3–7)
Median speech arrest in all right-sided
injections in s (range)*
8 (0–526) 5 (3–10)
Language lateralization results in patients with bilateral injections
Language left 283 (79.7%) 79 (76%)
Language bilateral dependent 46 (13%) 17 (16.3%)
Language bilateral independent 5 (1.4%) 2 (1.9%)
Language right 21 (5.9%) 6 (5.9%)
Sum 355 104
Objects presented during memory testing
Median objects presented left injection*** 16 12
Median objects presented right injection*** 16 10
Median objects retained left injection 8 8
Median objects retained right injection 10 10
Memory lateralization results in patients with bilateral injections
Memory left 216 (60.8%) 63 (60.6%)
Memory bilateral 30 (8.5%) 17 (16.3%)
Memory right 109 (30.7%) 24 (23.1%)
Sum 355 104
* p<0.05.
** p<0.01.
*** p<0.001.
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injection median left-sided speech arrest time was 121 s and
median right-sided speech arrest time was 5 s. Differences
between amobarbital and methohexital were signiﬁcant after left
and right injection (p < 0.05).
3.5.2. Right-sided language
In patients with right-sided language after amobarbital
injection median left-sided speech arrest duration was 2 s and
median right-sided speech arrest duration was 156 s. In six
patients with right-sided language lateralization after methohex-
ital injection median left-sided speech arrest was 19 s and median
right-sided speech arrest was 159 s. Results were not signiﬁcant
(n = 21).
3.5.3. Bilateral language
In patients with bilateral dependent language lateralization
after amobarbital injection, median left-sided speech arrest time
was 87 s and median right-sided speech arrest time 93 s. In
patients with bilateral dependent language lateralization after
methohexital injection, median speech arrest time on the left was
52 s and median right-sided speech arrest time on the right was
47 s. Differences between amobarbital and methohexital were not
signiﬁcant. In seven patients with bilateral independent language,
all values were by deﬁnition zero.
4. Discussion
Language testing during the Wada test can be successfully
performed with methohexital instead of amobarbital. Both
anesthetics appear equal in their ability to evaluate language
and memory lateralization. Speech arrest with amobarbital is
signiﬁcantly longer than with methohexital. Methohexital has a
shorter half-life (1–2 h) than amobarbital (10–40 h) allowing dose
titration. Shorter recovery after injection of methohexital allows
more efﬁcient bilateral hemispheric testing. Fast recovery may
require a modiﬁed memory testing protocol with fewer test items
given the shorter testing interval.
Advantages of methohexital include the shorter duration of the
anesthesia due to its’ shorter half-life and therefore faster testingintervals and less likelihood of involvement of the contralateral
hemisphere.4 Lesser degree of encephalopathy may also be one
explanation for the higher number of absolute retained memory
items in our series. Shorter testing times may allow more efﬁcient
testing. In our series, speech arrest duration after methohexital
was signiﬁcantly shorter. Additionally, recovery intervals could be
shortened by 15–30 min between injections. However, shorter
testing time may also limit time for memory testing. In our series
signiﬁcantly fewer memory test items could be presented. It is
possible that the increased percentage of retained items was
related to a shorter sedation effect and hence to the fact that the
patients were able to memorize objects better. Alternatively, this
could also be related to a smaller number of objects presented,
which may affect recall after the test. Additionally, shorter testing
periods and reduction in the number of presented objects may
further impact the already limited reliability of Wada memory
testing.11 Speech arrest cut-offs and duration of hemiparesis differ
with methohexital as compared to amobarbital. However, results
appear reproducible and allow for meaningful comparisons
between both hemispheres.
Methohexital is the only barbiturate with epileptogenic
properties.12 Several patients with seizures after methohexital
injection have been described13–15 and patients undergoing Wada
testing are more prone to develop seizures after methohexital
injection as compared to injection of amobarbital.16 After injection
of amobarbital, 0.7% had a seizure and 4.1% had a seizure after
methohexital injection.16
Results of the study need to be interpreted within the
retrospective study design setting. Only epilepsy surgery patients
at a tertiary epilepsy center were included. Additional limitations
include reliance on duration of speech arrest only as a means of
lateralizing language, the variable number of presented objects
due to differences in hemiparesis duration and additional potential
variations in the protocol hampering reliability and validity.11,17
Furthermore, we compared two different patient populations with
varying drug doses instead of comparing test data in the same
patient population. However, a prospective trial design with two
injections in the same patient might be difﬁcult due to ethical
consideration because of possible complications during the Wada
test such as carotid artery dissections and strokes.18,19
5. Conclusion
Methohexital can be used as an anesthetic agent in Wada
testing. There seems to be no difference between amobarbital and
methohexital in the determination of language and memory
lateralization. The shorter half-life of methohexital allows
repeated injections and shorter testing interval. A trade off is a
shortened length of the memory testing window and possible
induction of seizures. At Cleveland Clinic, it was decided to
continue testing with methohexital, although overall Wada test
numbers are declining. Despite methodological limitations includ-
ing calculation of comparable memory scores, shorter sedation
effect withmethohexital, epileptogenic properties ofmethohexital
and potential procedural variability our data provides further
clinical data on the comparison between methohexital and
amobarbital. Prospective studies involving comparison of meth-
ohexital and amobarbital and possibly propofol20,21 or etomidate22
in Wada testing, as well as other less invasive lateralization
techniques may help in the future to deﬁne the ideal agent, test
paradigm and protocol for selected patients.17
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